Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Inventory (2020 - 2025)

Cytek Biosciences' Inventory history spans 6 years, with the latest figure at $48.4 million for Q4 2025.

  • For Q4 2025, Inventory rose 10.33% year-over-year to $48.4 million; the TTM value through Dec 2025 reached $48.4 million, up 10.33%, while the annual FY2025 figure was $48.4 million, 10.33% up from the prior year.
  • Inventory reached $48.4 million in Q4 2025 per CTKB's latest filing, down from $51.6 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $69.5 million in Q1 2023 to a low of $26.7 million in Q2 2021.
  • Average Inventory over 5 years is $48.5 million, with a median of $48.4 million recorded in 2025.
  • Peak YoY movement for Inventory: surged 82.99% in 2023, then plummeted 30.02% in 2024.
  • A 5-year view of Inventory shows it stood at $32.2 million in 2021, then skyrocketed by 49.68% to $48.2 million in 2022, then rose by 26.42% to $60.9 million in 2023, then dropped by 27.9% to $43.9 million in 2024, then increased by 10.33% to $48.4 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Inventory are $48.4 million (Q4 2025), $51.6 million (Q3 2025), and $49.5 million (Q2 2025).